Suzhou Basecare Medical Corporation Limited provided consolidated earnings guidance for the six months ended June 30, 2023. For the period, the company expects total revenue to be within the range of RMB 79.4 million to RMB 87.8 million, representing an increase in the range of 15.7% to 28.0% from RMB 68.6 million for the six months ended June 30, 2022. The increase in revenue of the Group is mainly attributable to the sales of PGT-A kits and cryopreservation system.
Suzhou Basecare Medical Corporation Limited
Equities
2170
CNE100004BC1
Healthcare Facilities & Services
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.14 HKD | +6.47% | +9.74% | -8.94% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.94% | 68.27M | |
-16.58% | 8.25B | |
+39.20% | 3.58B | |
-39.11% | 2.46B | |
-8.06% | 2.46B | |
-6.85% | 2.38B | |
-19.01% | 1.55B | |
-40.66% | 1.21B | |
+7.56% | 1.11B | |
-14.42% | 1.03B |
- Stock Market
- Equities
- 2170 Stock
- News Suzhou Basecare Medical Corporation Limited
- Suzhou Basecare Medical Corporation Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023